Back to Search
Start Over
Guidelines on the prevention, diagnosis, and treatment of infective endocarditis (new version 2009): the Task Force on the Prevention, Diagnosis, and Treatment of Infective Endocarditis of the European Society of Cardiology (ESC). Endorsed by the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) and the International Society of Chemotherapy (ISC) for Infection and Cancer
- Source :
- European Heart Journal, European Heart Journal, Oxford University Press (OUP): Policy B, 2009, 30 (19), pp.2369-413. 〈10.1093/eurheartj/ehp285〉, European Heart Journal, Oxford University Press (OUP): Policy B, 2009, 30 (19), pp.2369-413. ⟨10.1093/eurheartj/ehp285⟩
- Publication Year :
- 2009
-
Abstract
- Guidelines and Expert Consensus Documents summarize and evaluate all currently available evidence on a particular issue with the aim of assisting physicians in selecting the best management strategy for an individual patient suffering from a given condition, taking into account the impact on outcome, as well as the risk/benefit ratio of particular diagnostic or therapeutic means. Guidelines are no substitutes for textbooks. The legal implications of medical guidelines have been discussed previously. A great number of Guidelines and Expert Consensus Documents have been issued in recent years by the European Society of Cardiology (ESC) as well as by other societies and organizations. Because of the impact on clinical practice, quality criteria for development of guidelines have been established in order to make all decisions transparent to the user. The recommendations for formulating and issuing ESC Guidelines and Expert Consensus Documents can be found on the ESC website (http://www.escardio.org/knowledge/guidelines/rules). In brief, experts in the field are selected and undertake a comprehensive review of the published evidence for management and/or prevention of a given condition. A critical evaluation of diagnostic and therapeutic procedures is performed including assessment of the risk/ benefit ratio. Estimates of expected health outcomes for larger societies are included, where data exist. The level of evidence and the strength of recommendation of particular treatment options are weighed and graded according to predefined scales, as outlined in Tables 1 and 2 . View this table: Table 1 Classes of recommendations View this table: Table 2 Levels of evidence The experts of the writing panels have provided disclosure statements of all relationships they may have which might be perceived as real or potential sources of conflicts of interest. These disclosure forms are kept on file at the European Heart House, headquarters of the ESC. Any changes in conflict of interest that arise during the writing period must be notified to …
- Subjects :
- media_common.quotation_subject
MEDLINE
Cardiology
030204 cardiovascular system & hematology
Health outcomes
03 medical and health sciences
0302 clinical medicine
[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases
medicine
Humans
Quality (business)
030212 general & internal medicine
ComputingMilieux_MISCELLANEOUS
Societies, Medical
media_common
Medical education
Endocarditis
business.industry
Conflict of interest
Evidence-based medicine
medicine.disease
3. Good health
Europe
[ SDV.MHEP.MI ] Life Sciences [q-bio]/Human health and pathology/Infectious diseases
Order (business)
Infective endocarditis
Table (database)
Cardiology and Cardiovascular Medicine
business
Subjects
Details
- ISSN :
- 15229645 and 0195668X
- Volume :
- 30
- Issue :
- 19
- Database :
- OpenAIRE
- Journal :
- European heart journal
- Accession number :
- edsair.doi.dedup.....6054a4d5099b95ac5e9b9308c031b35e
- Full Text :
- https://doi.org/10.1093/eurheartj/ehp285〉